Claim 1: Peptide compound having the formula (1): R¹-Z-R² (1) wherein Z is a peptide residue having the formula (2): Tyr-Aib-X³-GIy-Thr-Ser-Asp- Leu-Ser-X¹²-Gln-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-Phe-Ile-GIu-Trp-Leu-Lys-X²⁸-X²⁹-Gly-Pro-Ser-Ser-Gly- Ala-Pro-Pro-Pro-Ser-X⁴⁰ (2)；X3 represents other amino acids selected between Gln, Glu and HS； X12 represents other amino acids selected between ile and Lys； x1-83088 represents the rest of amino acids, which has a side chain composed of - nh-8322 group；a. The transverse chain group - nh-83222 was combined with - C (o) - r83099；en donde R puede ser un resto que comprende hasta 50 o hasta 100 tomos de carbono y opcionalmente hetero tomos seleccionados entre hal geno NOS y 2Fo PX representa un resto de amino cido seleccionado entre Asp y Glu X representa un resto de amino cido seleccionado entre Ser The results showed that x2 O1 represented the residual amino acids selected from ASP, Glu and Leu； x2 83212 represented the residual amino acids selected from ASN and ALA； x2 o8313 represented the residual amino acids selected from Gly, thr and D-Ala； X 8308040 was not present or represented Lys； R1 represented nh832222； and the remaining amino acids selected from Gly, thr and D-Ala were represented；R2 represents c-final group, selected from Oh to nh832222；Or salt or water Claim 27: the compound used in claim 26, which is present in the pharmaceutical ingredient as an active agent and has at least one acceptable pharmaceutical vehicle. Claim 31: compounds from any of the 26 to 30 claims for the treatment or prevention of hyperglycemia, type 2 diabetes and obesity.Reivindicación 1: Compuesto peptídico que tiene la fórmula (1): R¹-Z-R² (1) en donde Z es un resto peptídico que tiene la fórmula (2): Tyr-Aib-X³-GIy-Thr-Ser-Asp-Leu-Ser-X¹²-Gln-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-Phe-Ile-GIu-Trp-Leu-Lys-X²⁸-X²⁹-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X⁴⁰ (2)； X³ representa un resto de aminoácido seleccionado entre Gln, Glu y His； X¹² represent
